Argos Therapeutics Inc.

Charles Nicolette joined Argos Therapeutics in August 2003. Nicolette has extensive experience in the field of cancer vaccines and is the inventor on dozens of patent applications and issued patents relating to vaccine development for cancer and infectious diseases. He was formerly the Director of Antigen Discovery at Genzyme Molecular Oncology where he developed SPHERE technology, the subject of one of the largest biotechnology deals ever done in the field of tumor antigen discovery. He is an expert in cellular immunology and brings substantial immunological sophistication to Argos. Nicolette received his Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.

Lothar Finke, MD is Chief Medical Officer and Vice President of Regulatory Affairs at Argos Therapeutics. Dr. Finke has nine years of biotech oncology development experience in the pharmaceutical industry - both in Europe and the United States. Additionally, he has six years of clinical experience in surgical oncology and ten years of experience in molecular and cell biology. Prior to joining Argos, Dr. Finke worked for a number of companies, including EMD Pharmaceuticals, Lexigen Pharmaceuticals and Merck KGaA. Academically, Dr. Finke worked at the Max Delbrueck Center for Molecular Medicine, the Basel Institute for Immunology, Ruprecht Karls University of Heidelberg and Philipps University, Marburg/Lahn, Germany. As part of his industry experience, he is trained and experienced in regulatory affairs, drug safety and clinical development relevant to Europe, the United States, Canada and Japan. Dr. Finke received both his medical degree and cell biology doctorate from Philipps University of Marburg in Lahn, Germany.

Jeffrey Abbey joined Argos Therapeutics in September 2002. Before joining Argos, Abbey was Vice President of Business Development and Finance for Internet Appliance Network (IAN), a venture-backed information technology company based in New York City. Prior to joining IAN, he was a partner in Eilenberg and Krause, a boutique corporate law firm, where he acted as business counsel for a number of life sciences and other emerging technology companies. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. He holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.

Mike Cable has been the Validation Manager at Argos Therapeutics in Durham, NC for over five years. His responsibilities include equipment and facility qualification activities for GMP manufacturing of autologous immunotherapeutic cancer and HIV products currently in Phase 2 clinical trials. Mike started his career as an Electronics Technician in the Navy Nuclear Power Program, serving as Reactor Operator aboard the USS Los Angeles submarine. After leaving the Navy, Mike spent 11 years at Performance Solutions performing technical services for the pharmaceutical industry, highlighted by an assignment to Eli Lilly Corporate Process Automation managing Instrument Qualification projects for new facility startups. His practical experience in instrumentation and controls led him to his current career path in Validation, which has been his main focus for the past 12 years.